Dynport Vaccine Company LLC
UEI LXNEGTYDR755 · MD · subsidiary of Wico Limited · SAM.gov record ↗
Obligations by agency
- Department Of Defense$3.0M
- Department Of Health And Human Services$-6.7M
Obligations by NAICS
Monthly obligations
Contracts ending within 18 months (recompete watch)
- 75N93022F00001 ↗$435K
TASK ORDER 75N93022F00001 BASE AWARD
- Ends
- Jan 12, 2027
- Started
- Jan 20, 2022
- Agency
- National Institutes Of Health
- NAICS
- 541715
- W911QY13C0056 ↗$-317K
EXTEND DEADLINE FOR TERMINATION SETTLEMENT PROPOSAL SUBMISSION DATE TO 12 MARCH 2026 UNDER TERMINATED CONTRACT FOR FDA LICENSURE OF A BIOSCAVENGER PROPHYLAXIS.
- Ends
- Mar 10, 2027
- Started
- May 8, 2013
- Agency
- Department Of The Army
- NAICS
- 541711
| PIID | Description | Agency | NAICS | Obligated | Start | End |
|---|---|---|---|---|---|---|
| 75N93022F00001 ↗ | TASK ORDER 75N93022F00001 BASE AWARD | National Institutes Of Health | 541715 | $435K | Jan 20, 2022 | Jan 12, 2027 |
| W911QY13C0056 ↗ | EXTEND DEADLINE FOR TERMINATION SETTLEMENT PROPOSAL SUBMISSION DATE TO 12 MARCH 2026 UNDER TERMINATED CONTRACT FOR FDA LICENSURE OF A BIOSCAVENGER PROPHYLAXIS. | Department Of The Army | 541711 | $-317K | May 8, 2013 | Mar 10, 2027 |
Largest awards
- W911QY21C0093 ↗$3.3M
PERFORMANCE OF STABILITY TESTING ON RF1V DRUG PRODUCT (DP).
- Ends
- Aug 14, 2026
- Started
- Aug 5, 2021
- Agency
- Department Of The Army
- NAICS
- 541715
- 75N93022F00001 ↗$435K
TASK ORDER 75N93022F00001 BASE AWARD
- Ends
- Jan 12, 2027
- Started
- Jan 20, 2022
- Agency
- National Institutes Of Health
- NAICS
- 541715
- 75N93021F00202 ↗$32K
PHASE 1 CLINICAL TRIAL UNIT FOR THERAPEUTICS AGAINST INFECTIOUS DISEASES
- Ends
- Jan 30, 2025
- Started
- May 12, 2021
- Agency
- National Institutes Of Health
- NAICS
- 541711
- 75N93025D00025 ↗$10K
"EVALUATION AND TESTING SERVICES (ETS) FOR VACCINES AND OTHER BIOLOGICS FOR INFECTIOUS DISEASES.
- Ends
- —
- Started
- Sep 29, 2025
- Agency
- National Institutes Of Health
- NAICS
- 541715
- 0002 ↗$6K
TAFENOQUINE CLINICAL TRIALS
- Ends
- Jul 30, 2022
- Started
- Mar 21, 2017
- Agency
- Defense Health Agency
- NAICS
- 541712
EPCTU
- Ends
- Jul 14, 2025
- Started
- May 14, 2023
- Agency
- National Institutes Of Health
- NAICS
- 541715
PHASE I TASK AREA B -21-0013 - BASE
- Ends
- Dec 14, 2024
- Started
- Dec 13, 2021
- Agency
- National Institutes Of Health
- NAICS
- 541711
EARLY PHASE CLINICAL TRIAL UNITS (EPCTU)
- Ends
- —
- Started
- Jan 13, 2022
- Agency
- National Institutes Of Health
- NAICS
- 541715
- 75N93020F00001 ↗$-352
1500005I DYNPORT VACCINE COMPANY
- Ends
- Dec 13, 2020
- Started
- Dec 14, 2019
- Agency
- National Institutes Of Health
- NAICS
- 541711
- W911QY13C0056 ↗$-317K
EXTEND DEADLINE FOR TERMINATION SETTLEMENT PROPOSAL SUBMISSION DATE TO 12 MARCH 2026 UNDER TERMINATED CONTRACT FOR FDA LICENSURE OF A BIOSCAVENGER PROPHYLAXIS.
- Ends
- Mar 10, 2027
- Started
- May 8, 2013
- Agency
- Department Of The Army
- NAICS
- 541711
- HHSO100200600013C ↗$-7.2M
CLOSE CONTRACT AND DEOBLIGATE EXCESS FUNDS
- Ends
- Jan 29, 2012
- Started
- Apr 30, 2006
- Agency
- Office Of Assistant Secretary For Preparedness And Response
- NAICS
- 325414
| PIID | Description | Agency | NAICS | Obligated | Start | End |
|---|---|---|---|---|---|---|
| W911QY21C0093 ↗ | PERFORMANCE OF STABILITY TESTING ON RF1V DRUG PRODUCT (DP). | Department Of The Army | 541715 | $3.3M | Aug 5, 2021 | Aug 14, 2026 |
| 75N93022F00001 ↗ | TASK ORDER 75N93022F00001 BASE AWARD | National Institutes Of Health | 541715 | $435K | Jan 20, 2022 | Jan 12, 2027 |
| 75N93021F00202 ↗ | PHASE 1 CLINICAL TRIAL UNIT FOR THERAPEUTICS AGAINST INFECTIOUS DISEASES | National Institutes Of Health | 541711 | $32K | May 12, 2021 | Jan 30, 2025 |
| 75N93025D00025 ↗ | "EVALUATION AND TESTING SERVICES (ETS) FOR VACCINES AND OTHER BIOLOGICS FOR INFECTIOUS DISEASES. | National Institutes Of Health | 541715 | $10K | Sep 29, 2025 | — |
| 0002 ↗ | TAFENOQUINE CLINICAL TRIALS | Defense Health Agency | 541712 | $6K | Mar 21, 2017 | Jul 30, 2022 |
| 75N93023F00001 ↗ | EPCTU | National Institutes Of Health | 541715 | $0 | May 14, 2023 | Jul 14, 2025 |
| 75N93022F00057 ↗ | PHASE I TASK AREA B -21-0013 - BASE | National Institutes Of Health | 541711 | $0 | Dec 13, 2021 | Dec 14, 2024 |
| 75N93022D00016 ↗ | EARLY PHASE CLINICAL TRIAL UNITS (EPCTU) | National Institutes Of Health | 541715 | $0 | Jan 13, 2022 | — |
| 75N93020F00001 ↗ | 1500005I DYNPORT VACCINE COMPANY | National Institutes Of Health | 541711 | $-352 | Dec 14, 2019 | Dec 13, 2020 |
| W911QY13C0056 ↗ | EXTEND DEADLINE FOR TERMINATION SETTLEMENT PROPOSAL SUBMISSION DATE TO 12 MARCH 2026 UNDER TERMINATED CONTRACT FOR FDA LICENSURE OF A BIOSCAVENGER PROPHYLAXIS. | Department Of The Army | 541711 | $-317K | May 8, 2013 | Mar 10, 2027 |
| HHSO100200600013C ↗ | CLOSE CONTRACT AND DEOBLIGATE EXCESS FUNDS | Office Of Assistant Secretary For Preparedness And Response | 325414 | $-7.2M | Apr 30, 2006 | Jan 29, 2012 |